GSK takes billion-dollar drug fight with Gilead to top AIDS meeting [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting | Reuters 4 Min Read LONDON (Reuters) - GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world’s leading AIDS conference next month by showcasing detailed results from its new two-drug treatment. The drugmakers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach. Deborah Waterhouse, head of GSK’s majority-owned HIV business ViiV Healthcare, aims to overtake Gilead as market leader in the $26 billion-a-year HIV market by the mid-2020s, assuming the gamble on two-drug combinations pans out. She has her work cut out. Gilead currently has a market share of 52 percent against GSK’s 22 percent - a breakdown that has changed little this year, despite the successful launch of Gilead’s new three-drug medici
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? [Seeking Alpha]Seeking Alpha
- Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect? [Yahoo! Finance]Yahoo! Finance
- Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/6/24 - Miss
GILD
Sec Filings
- 4/2/24 - Form 4
- 4/1/24 - Form 144
- 3/29/24 - Form 4
- GILD's page on the SEC website